Systemic Therapy for Stage IV Melanoma: Current Standards, Questions, and Investigations

Download this slideset to gain key insights into current therapeutic strategies in advanced melanoma, including optimal approaches for managing CNS metastases.
Michael A. Davies, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 681 KB
Released: November 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation

Related Content

Part 2 of KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in high-risk stage III melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

5-year update of the COLUMBUS trial of encorafenib + binimetinib in BRAF V600-mutant melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

ABC study of nivolumab plus ipilimumab update at 5 years in patients with melanoma brain metastases from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

LEAP 004 trial update on lenvatinib + pembrolizumab in patients with advanced melanoma and progression on anti-PD-1/PD-L1 therapy from ASCO 2021 reported by Clinical Care Options (CCO)

Released: June 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue